| Index | — | P/E | — | EPS (ttm) | -0.97 | Insider Own | 25.70% | Shs Outstand | 1.06B | Perf Week | 1.79% |
| Market Cap | 8.43B | Forward P/E | — | EPS next Y | -0.11 | Insider Trans | -0.20% | Shs Float | 115.20M | Perf Month | -22.74% |
| Enterprise Value | 8.87B | PEG | — | EPS next Q | -0.07 | Short Float | — | Perf Quarter | 14.39% | ||
| Income | -992.00M | P/S | 51.06 | EPS this Y | — | Short Ratio | 11.13 | Perf Half Y | 7.00% | ||
| Sales | 165.00M | P/B | — | EPS next Y | — | ROA | -157.89% | Short Interest | 122.95M | Perf YTD | 301.52% |
| Book/sh | -0.99 | P/C | 23.60 | EPS next 5Y | — | ROE | — | 52W High | 12.43 -33.31% | Perf Year | 236.86% |
| Cash/sh | 0.34 | P/FCF | — | EPS past 3/5Y | — | ROIC | -45.01% | 52W Low | 1.95 325.13% | Perf 3Y | 287.80% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — 157.40% | Gross Margin | 94.63% | Volatility | 6.54% 7.56% | Perf 5Y | -4.22% |
| Dividend TTM | — | EV/Sales | 53.78 | EPS Y/Y TTM | — | Oper. Margin | -151.88% | ATR (14) | 0.65 | Perf 10Y | 19.91% |
| Dividend Ex-Date | — | Quick Ratio | 5.70 | Sales Y/Y TTM | 189.47% | Profit Margin | -598.56% | RSI (14) | 40.71 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 5.72 | EPS Q/Q | -120.00% | SMA20 | -12.38% | Beta | 0.21 | Target Price | 14.00 |
| Payout | 0.00% | Debt/Eq | — | Sales Q/Q | 96.15% | SMA50 | -8.73% | Rel Volume | 0.79 | Prev Close | 7.95 |
| Employees | 688 | LT Debt/Eq | — | Earnings | Nov 03 | SMA200 | 0.35% | Avg Volume | 11.37M | Price | 8.29 |
| IPO Date | Jul 28, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -229.41% 3.10% | Net Debt/EBITDA | — | Volume | 9,019,659 | Change | 4.28% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-14-26 | Reiterated | Piper Sandler | Overweight | $12 → $16 |
| May-08-26 | Reiterated | BTIG | Buy | $13 → $12 |
| Mar-04-26 | Reiterated | Piper Sandler | Overweight | $7.00 → $12 |
| Feb-23-26 | Reiterated | HC Wainwright & Co. | Buy | $15 |
| Jan-20-26 | Reiterated | Piper Sandler | Overweight | $7.00 |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight | |
| Jan-10-25 | Initiated | BTIG | Buy | $6.00 |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Aug-03-22 | Reiterated | Jefferies | Buy | $8.00 |
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 165 | 113 | 15 | 1 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 8 | 1 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 157 | 113 | 15 | 1 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 166 | 147 | 169 | 130 | — | — | — | — | — | |
| Research and Development | 235 | 208 | 190 | 232 | — | — | — | — | — | |
| Other Operating Expense | 9 | 14 | 0 | 1 | — | — | — | — | — | |
| Operating Income | -253 | -256 | -344 | -362 | — | — | — | — | — | |
| Interest Expense | 83 | 113 | 132 | 87 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -658 | 17 | 62 | -135 | — | — | — | — | — | |
| Net Income Before Taxes | -992 | -352 | -414 | -584 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -992 | -351 | -414 | -583 | — | — | — | — | — | |
| Net Income From Continuing Operations | -992 | -351 | -414 | -584 | — | — | — | — | — | |
| Net Income | -992 | -351 | -414 | -583 | — | — | — | — | — | |
| EPS (Recurring) | -0.97 | -0.38 | -0.59 | -1.15 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.97 | -0.38 | -0.59 | -1.15 | — | — | — | — | — | |
| EPS (Diluted) | -0.97 | -0.38 | -0.62 | -1.15 | — | — | — | — | — | |
| EBITDA | -893 | -224 | -264 | -479 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 52.75 | 16.12 | 118.95 | 2,555.18 | — | — | — | — | — | |
| Gross Margin | 95.15 | 100.00 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | -153.33 | -226.55 | -2,293.33 | -36,200.00 | — | — | — | — | — | |
| Net Margin | -601.21 | -310.62 | -2,760.00 | -58,300.00 | — | — | — | — | — | |
| Shares Outstanding | 1,050 | 920 | 697 | 509 | — | — | — | — | — | |
| Market Capitalization | 8,705 | 1,822 | 1,784 | 2,555 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Simon Barry J. | Director | Oct 05 '26 | Sale | 10.75 | 25,000 | 268,760 | 2,777,788 | Oct 06 |
| Cohen Cheryl | Director | Oct 02 '26 | Option Exercise | 2.98 | 55,979 | 166,817 | 181,365 | Oct 06 |
| Cohen Cheryl | Director | Oct 02 '26 | Sale | 10.50 | 81,056 | 851,088 | 100,309 | Oct 06 |
| Cohen Cheryl | Director | Jul 02 '26 | Option Exercise | 2.98 | 55,979 | 166,817 | 256,596 | Jul 06 |
| Cohen Cheryl | Director | Jul 02 '26 | Sale | 9.50 | 131,210 | 1,246,941 | 125,386 | Jul 06 |
| Selecky Christobel | Director | Jul 01 '26 | Option Exercise | 2.99 | 159,478 | 476,489 | 159,478 | Jul 06 |
| Selecky Christobel | Director | Jul 01 '26 | Sale | 9.02 | 159,478 | 1,439,066 | 0 | Jul 06 |
| Selecky Christobel | Director | Jun 30 '26 | Option Exercise | 2.98 | 1,000 | 2,983 | 1,000 | Jul 01 |
| Selecky Christobel | Director | Jun 30 '26 | Sale | 9.00 | 1,000 | 9,000 | 0 | Jul 01 |
| Selecky Christobel | Director | Jun 29 '26 | Option Exercise | 2.94 | 95,722 | 281,388 | 95,722 | Jul 01 |
| Selecky Christobel | Director | Jun 29 '26 | Sale | 9.01 | 95,722 | 862,216 | 0 | Jul 01 |
| Simon Barry J. | Director | Jun 24 '26 | Sale | 7.88 | 25,000 | 196,908 | 2,802,788 | Jun 26 |
| Simon Barry J. | Director | Jun 04 '26 | Sale | 7.18 | 23,033 | 165,306 | 2,827,788 | Jun 05 |
| Simon Barry J. | Director | Feb 24 '26 | Sale | 12.01 | 75,000 | 900,788 | 2,850,821 | Feb 26 |
| Simon Barry J. | Director | Feb 23 '26 | Sale | 10.25 | 165,000 | 1,691,102 | 2,925,821 | Feb 24 |